Bionure

1 known investors

Bionure develops next-generation therapies using therapeutic RNA, chemical compounds, peptidomimetics, and oligonucleotides to treat rare neurodegenerative and neuro-inflammatory diseases such as ALS, Rett syndrome, ataxia, and Huntington's disease. Founded in 2009, the company works on drugs for the nervous system spanning pre-clinical through Phase II development.

BiotechDeep TechHealthtech